UB Paderborn / Katalog / Suche / in CDI

PCN68 Pharmacoeconomic Evaluation of Rituximab as Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Real-World Population Based Study

Value in health, 2012-11, Vol.15 (7), p.A421-A421

2012

Volltextzugriff (PDF)

L’Arni-Cas

Revue française d'allergologie (2009), 2023-04, Vol.63 (3), p.103420, Article 103420

2023

Volltextzugriff (PDF)

Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada

Current oncology (Toronto), 2020-12, Vol.27 (6), p.e578-589

2020

Volltextzugriff (PDF)

2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)

European journal of cancer (1990), 2015-09, Vol.51, p.S379-S380

2015

Volltextzugriff (PDF)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

European journal of cancer (1990), 2015-09, Vol.51, p.S532-S532

2015

Volltextzugriff (PDF)

POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal

Value in health, 2022-01, Vol.25 (1), p.S69-S70

2022

Volltextzugriff (PDF)

Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

Annals of oncology, 2019-10, Vol.30, p.v65

2019

Volltextzugriff (PDF)

193P - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

Annals of oncology, 2019-10, Vol.30, p.v65-v65

2019

Volltextzugriff (PDF)

ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi449-vi449

2016

Volltextzugriff (PDF)

Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab-Based Treatment in Canada

Current oncology (Toronto), 2020-12, Vol.27 (6), p.578

2020

Volltextzugriff (PDF)

LBA-01 Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC)

Annals of oncology, 2015-06, Vol.26, p.iv117

2015

Volltextzugriff (PDF)

141O Efficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

Overall Survival According to Patient Subgroups: Results from a Pooled Analysis of 5 Observational or Phase Iv Studies of Bevacizumab in Metastatic Colorectal Cancer

Annals of oncology, 2014-09, Vol.25, p.iv176

2014

Volltextzugriff (PDF)

AT-17 RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v12-v12

2014

Volltextzugriff (PDF)

AT-18 SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v12-v12

2014

Volltextzugriff (PDF)

193PImpact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.6136

2009

Volltextzugriff (PDF)

520POVERALL SURVIVAL ACCORDING TO PATIENT SUBGROUPS: RESULTS FROM A POOLED ANALYSIS OF 5 OBSERVATIONAL OR PHASE IV STUDIES OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv176-iv177

2014

Volltextzugriff (PDF)

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Current medical research and opinion, 2019-12, Vol.35 (12), p.2079-2087

2019

Volltextzugriff (PDF)

Seismoelectric Exploration: Theory, Experiments, and Applications

1, 2020

Volltextzugriff (PDF)

Review: Some low-frequency electrical methods for subsurface characterization and monitoring in hydrogeology

Hydrogeology journal, 2012-06, Vol.20 (4), p.617-658

2012

Volltextzugriff (PDF)

Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study

Blood, 2012-11, Vol.120 (21), p.4277-4277

2012

Volltextzugriff (PDF)

Complex conductivity of soils

Water resources research, 2017-08, Vol.53 (8), p.7121-7147

2017

Volltextzugriff (PDF)

Spectral induced polarization porosimetry

Geophysical journal international, 2014-08, Vol.198 (2), p.1016-1033

2014

Volltextzugriff (PDF)

Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087

Current medical research and opinion, 2020-07, Vol.36 (7), p.1129-1130

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

PCN68 Pharmacoeconomic Evaluation of Rituximab as Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Real-World Population Based Study

L’Arni-Cas

Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada

2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal

Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

193P - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC)

Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab-Based Treatment in Canada

LBA-01 Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC)

141O Efficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)

Overall Survival According to Patient Subgroups: Results from a Pooled Analysis of 5 Observational or Phase Iv Studies of Bevacizumab in Metastatic Colorectal Cancer

AT-17 RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

AT-18 SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

193PImpact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab

520POVERALL SURVIVAL ACCORDING TO PATIENT SUBGROUPS: RESULTS FROM A POOLED ANALYSIS OF 5 OBSERVATIONAL OR PHASE IV STUDIES OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Seismoelectric Exploration: Theory, Experiments, and Applications

Review: Some low-frequency electrical methods for subsurface characterization and monitoring in hydrogeology

Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study

Complex conductivity of soils

Spectral induced polarization porosimetry

Suchergebnisse filtern